Question explored with the scientific record
Conversation so far
- 1 benefit of 1 mg melatonic/night for sleep
- 2 benefit of 1/2 mg klonopin for sleep
- 3 reasonably safe drug for chronic insomnia
- 4 what about 25 mg hydroxyzine for sleep in elderly
- 5 what can an elderly person with life-long insomnia try, to finally get a few years of decent sleep
Answered on this page ↓
what can an elderly person with life-long insomnia try, to finally get a few years of decent sleep
The short version: for lifelong insomnia in old age, the best-evidenced thing is behavioral therapy, and the honest gain is modest, not a cure.
Cognitive behavioral therapy for insomnia (CBT-I) is the one approach with randomized trials in people over 60. A systematic review of those trials found a mild benefit: sleep-maintenance therapy cut time awake after falling asleep by roughly 22 to 24 minutes, and one trial added about 14.6 minutes of total sleep by diary [1]. That is real but small. Bright light and exercise had limited evidence in the same review, and no bright-light trial met its inclusion criteria [1].
The drug evidence is thinner than it looks. Low-dose doxepin (6 mg) beat placebo over four weeks in older adults with chronic insomnia, improving sleep maintenance and total sleep time [2]. Four weeks is not lifelong use, and the gains were modest. A 2025 network meta-analysis of 102 trials found most insomnia drugs raised the risk of drowsiness, dizziness, or headache versus placebo, and doxepin was the exception, with lower headache risk [3]. Suvorexant has a trial in older adults with Alzheimer's and insomnia showing better sleep maintenance than placebo [4][5], but that is a different population than a cognitively intact elder.
| Option | Best evidence in elderly | Size of effect |
|---|---|---|
| CBT-I | RCTs in 60+ [1] | ~22 min less wake time [1] |
| Doxepin 6 mg | 4-week RCT, elderly [2] | Modest sleep gain [2] |
| Suvorexant | Alzheimer's + insomnia trial [4][5] | Better than placebo [4] |
| Bright light | No qualifying trials [1] | Not established [1] |
What this evidence cannot see: no trial here followed lifelong insomniacs for years, and none compared CBT-I head to head against drugs over the long haul. The behavioral approach is the safer bet because the harms are minimal, not because the benefit is large.
My call: start with CBT-I, add low-dose doxepin only if sleep maintenance stays broken, and expect incremental gains, not transformation. Confidence: moderate on CBT-I being first-line, low on any single drug delivering years of good sleep.
Sources used 5
-
A systematic review of non-pharmacological therapies for sleep problems in later life
A systematic review of randomized controlled trials evaluating non-pharmacological therapies—cognitive-behavioral therapy, bright light, and exercise—for sleep problems in adults aged 60 and over, finding a mild benefit for CBT with limited evidence for bright light or exercise.
DOI: 10.1016/s1087-0792(03)00026-1 -
Efficacy and safety of doxepin 6mg in a four-week outpatient trial of elderly adults with chronic primary insomnia
This study evaluates the efficacy and safety of low-dose doxepin (6 mg) in improving sleep maintenance and duration in elderly adults with chronic primary insomnia over a four-week period.
DOI: 10.1016/j.sleep.2011.09.006 -
Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis
In 102 RCTs (35,700 adults with primary insomnia), a network meta-analysis found most insomnia drugs increased risks of somnolence, dizziness, headache, dysgeusia, dry mouth, or nausea/vomiting versus placebo, none increased serious AEs, and doxepin lowered headache and somnolen…
DOI: 10.3389/fpsyt.2025.1461166 -
Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia
Narrative review finds suvorexant, the first dual orexin receptor antagonist, efficacious and generally well tolerated for insomnia across diverse populations, with a distinct mechanism and low dependence risk.
DOI: 10.52965/001c.67898 -
Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders
A comprehensive review of orexin/hypocretin signaling in Alzheimer’s disease (AD), evaluating sleep disturbances and the clinical evidence for dual orexin receptor antagonists (DORAs) and selective orexin-2 receptor antagonists (2-SORAs) in treating AD-related sleep disorders an…
DOI: 10.1007/s40265-024-02096-3